openPR Logo
Press release

Investigation announced for Investors in AbbVie Inc. (NYSE: ABBV) concerning potential Wrongdoing

07-01-2022 04:23 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in AbbVie Inc. (NYSE: ABBV) shares over possible breaches of fiduciary d

An investigation on behalf of current long term investors in AbbVie Inc. (NYSE: ABBV) shares over possible breaches of fiduciary d

An investigation was announced for long-term investors in shares of AbbVie Inc. (NYSE: ABBV) concerning potential breaches of fiduciary duties by certain directors of AbbVie Inc..

Investors who are current long term investors in AbbVie Inc. (NYSE: ABBV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NYSE: ABBV stocks follows a lawsuit filed against AbbVie Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: ABBV stocks, concerns whether certain AbbVie Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the Defendants misrepresented and/or failed to disclose that safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors, that as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq, and that therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

Those who purchased shares of AbbVie Inc. (NYSE: ABBV) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in AbbVie Inc. (NYSE: ABBV) concerning potential Wrongdoing here

News-ID: 2668455 • Views: 474

More Releases from Shareholders Foundation

Deadline on August 15th coming up in Lawsuit for Investors in Unilever PLC (NYSE …
A deadline is coming up on August 15, 2022 in the lawsuit filed for certain investors of Unilever PLC (NYSE: UL) over alleged securities laws violations by Unilever PLC. Investors who purchased shares of Unilever PLC (NYSE: UL) have certain options and there are strict and short deadlines running. Deadline: August 15, 2022. NYSE: UL stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Investors in shares of Aurinia Pharmaceuticals Inc. …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Aurinia Pharmaceuticals Inc.. Investors who are current long term investors in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: AUPH stocks follows a lawsuit filed against Aurinia
Investigation announced for Investors in Hannon Armstrong Sustainable Infrastruc …
An investigation was announced over potential securities laws violations by Hannon Armstrong Sustainable Infrastructure Capital, Inc. in connection with certain financial statements. Investors who purchased shares of Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NYSE: HASI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on whether a series of statements by Hannon Armstrong Sustainable
Lawsuit filed for Investors in shares of Molecular Partners AG (NASDAQ: MOLN)
An investor, who purchased shares of Molecular Partners AG (NASDAQ: MOLN), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Molecular Partners AG (NASDAQ: MOLN in connection with certain allegedly false and misleading statements. Investors who purchased shares of Molecular Partners AG (NASDAQ: MOLN) have certain options and for certain investors are short and strict deadlines running. Deadline: September 12, 2022. NASDAQ: MOLN investors should contact

All 5 Releases


More Releases for AbbVie

Immunotherapy Drugs Market Next Big Thing | Amgen, GlaxoSmithKline, AbbVie
AMA Research added a comprehensive research document of 200+ pages on 'Immunotherapy Drugs' market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are: F. Hoffmann-La Roche AG (Switzerland)
Hypercalcemia Treatment Market Next Big Thing | Novartis, DiaSorin, Fujirebio, A …
AMA Research added a comprehensive research document of 200+ pages on 'Hypercalcemia Treatment' market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are: Dr. Reddy's Laboratories Ltd. (India) Novartis
Global Dermatology Drug Market 2018 - AbbVie, Bayer, Pfizer
Apex Market Reports, recently published a detailed market research study focused on the “Dermatology Drug Market” across the global, regional and country level. The report provides 360° analysis of “Dermatology Drug Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Dermatology Drug on
Dr. Eric Blomme, AbbVie, Chair Invite & Interview Snippet for ADMET
The 13th annual ADMET conference, commencing 9 – 10 July 2018 in London, UK, will be chaired by Dr Eric Blomme, Vice President of Development Biological Sciences at AbbVie. Ahead of this year’s conference, Dr Blomme invites ADMET professionals and discusses the event in his exclusive interview with SMi, both of which are now available to download on the event website. Dr Eric Blomme has held several positions at Abbott/AbbVie, including
Global Cytokines Market 2018 - AbbVie, Roche, Pfizer, Sanofi, Biocon
Apex Market Reports, recently published a detailed market research study focused on the “Cytokines Market” across the global, regional and country level. The report provides 360° analysis of “Cytokines Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Cytokines on the basis of
Global Autoimmune Drugs Market 2018-2023 AbbVie, Johnson & Johnson, Biogen
Autoimmune Drugs Market Research 2018 A market study "Global Autoimmune Drugs Market" examines the performance of the Autoimmune Drugs market 2018. It encloses an in-depth Research of the Autoimmune Drugs market state and the competitive landscape globally. This report analyzes the potential of Autoimmune Drugs market in the present and the future prospects from various angles in detail. The Global Autoimmune Drugs Market 2018 report includes Autoimmune Drugs market Revenue, market Share,